Western Kentucky University

TopSCHOLAR®
Honors College Capstone Experience/Thesis
Projects

Honors College at WKU

Spring 4-26-2018

Investigating the Synergistic Effects of Two
Curcuminoids and Cisplatin on Cancer Cell
Migration
Blaine Patty
Western Kentucky University, blaine.patty739@topper.wku.edu

Follow this and additional works at: https://digitalcommons.wku.edu/stu_hon_theses
Part of the Biology Commons, Oncology Commons, and the Pharmacology Commons
Recommended Citation
Patty, Blaine, "Investigating the Synergistic Effects of Two Curcuminoids and Cisplatin on Cancer Cell Migration" (2018). Honors
College Capstone Experience/Thesis Projects. Paper 727.
https://digitalcommons.wku.edu/stu_hon_theses/727

This Thesis is brought to you for free and open access by TopSCHOLAR®. It has been accepted for inclusion in Honors College Capstone Experience/
Thesis Projects by an authorized administrator of TopSCHOLAR®. For more information, please contact topscholar@wku.edu.

INVESTIGATING THE SYNERGISTIC EFFECTS OF TWO CURCUMINOIDS AND
CISPLATIN ON CANCER CELL MIGRATION

A Capstone Project Presented in Partial Fulfillment
of the Requirements for the Degree Bachelor of Science
with Honors College Graduate Distinction at
Western Kentucky University

By
Blaine Patty
May 2018

*****

CE/T Committee:
Dr. Michael Smith, Chair
Dr. Jerry Monroe
Dr. Christopher Keller

Copyright by
Blaine Patty
2018

I dedicate this thesis to my parents, Rick and Rita, and my brother, Tyler, for supporting
me during my collegiate career. Also, I dedicate this to all those who are fighting cancer
and to the families of those with the disease.

ACKNOWLEDGEMENTS

I would like to thank Dr. Michael Smith for his mentorship and allowing me to
work in his lab. I would also like to thank Dr. Jerry Monroe for working closely with me
on the project, and all the guidance he has given during the duration of the project. This
project was financially supported by a WKU Faculty-Undergraduate Student Experience
grant, WKU Research and Creative Activities Program grant #17-8031, and NIH 1 R15
CA188890-01A1 grant. Finally, I would like to thank the Department of Biology, the
WKU Biotechnology Center, and the Mahurin Honors College.

iv

ABSTRACT

Cisplatin is a common chemotherapy drug used to treat various cancers; however, it is
relatively ineffective against many cancers, including several types of lung cancer. One
approach that could improve cisplatin’s effect is to combine it with another drug that
produces a synergistic response greater than either drug alone. Curcumin, a naturally
occurring plant compound, has been investigated for synergisms in conjunction with
cisplatin chemotherapy, but curcumin use is hampered by its low bioavailability. This
project investigated whether two synthetic curcumin analogs, EF-24 and CLEFMA
(curcuminoids), which have greater solubility than curcumin, could, when combined with
cisplatin, decrease the migration rate of the non-small cell lung cancer cell line, A549.
Dishes of A549 were treated with media only control, cisplatin, EF-24, CLEFMA or
combinations of cisplatin with either curcumin analog. Then, a scratched clearing was
introduced through the cells and photographs were taken at timed intervals to determine
if either curcuminoid increased the effect of cisplatin by slowing cell migration into the
cleared area. We found that when combined with cisplatin, both curcuminoids increased
the effectiveness of cisplatin against cancer cell migration and reduced wound recovery.
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INTRODUCTION
Nearly 1.7 million people were diagnosed with cancer in the United States in
2017, and around 600,000 of them are projected to die from this disease (Siegel et al.,
2017). The sheer number of these cancer statistics suggests that further improvements to
current cancer treatments are required.
One hallmark of cancer is its ability to metastasize or migrate to surrounding
tissue or to other parts of the body (Hanahan & Weinberg, 2011), and this aspect of
cancer is now a target for many therapeutic interventions. Cisplatin is a commonly used
platinum-based chemotherapy that is effective against bladder, ovarian, and testicular
cancer (Dasari & Tchounwou, 2014). This platinum compound can also slow cancer cell
migration (Yin et al., 2018). However, cisplatin typically is not effective against many
cancers, including non-small cell lung cancers, often due to the development of resistance
to this drug (Shen et al., 2012). Therefore, there is considerable interest in improving
cisplatin’s effectiveness, including enhancing its effect against migration.
Curcumin is a naturally occurring liposoluble pigment that is extracted from the
rhizome of Curcuma longa, and is commonly used in Asian cuisine (Ali et al., 2017; Liu
et al., 2017; Shen et al., 2017). It also has been used as a pharmacological agent in
Chinese medicine due to its anti-inflammatory, anticoagulant, and antioxidant properties.
In addition, it possesses anticancer effects by suppressing the mTOR/PI3K/AKT pathway
which induces apoptosis and autophagy (Wang et al., 2017). Curcumin is currently being
tested on non-small cell lung cancers including the cancer cell line, A549 (Liu et al.,
2017; Shen et al., 2017; Shi et al., 2017a; Wang et al., 2017). However, curcumin
exhibits low-bioavailability, i.e. low solubility, which reduces its effectiveness (Skoupa et
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al, 2017). Due to this, there is considerable interest in developing synthetic curcumin
analogs (curcuminoids) that exhibit higher bioavailability but retain curcumin’s
anticancer efficacy.
The two curcuminoids studied in this project were (3E,5E)-3,5-bis[(2fluorophenyl)methylene]-4-piperidinone (EF-24), and 4-[3,5Bis[(2-chlorophenyl)
methylene]-4-oxo-1-piperidinyl]-4-oxo-2-butenoic acid (CLEFMA). These two
curcuminoids have higher bioavailability than curcumin, and both have anticancer effects
(Sahoo et al, 2012; Skoupa et al., 2017). EF-24 has been shown to induce apoptosis in
K562 myelogenous leukemia cancer cells, and CLEFMA has been shown to induce
apoptosis in H441 lung adenocarcinoma cancer cells (Sahoo et al, 2012; Skoupa et al.,
2017). Although these curcuminoids do have anticancer effects, their effect against
cancer cell migration and in combination with cisplatin has yet to be determined.
The purpose of my research project was to investigate if EF-24 and CLEFMA
have a synergistic effect with cisplatin against A549 cancer cell migration. A549 is a
non-small cell lung carcinoma cell line that is commonly used in cancer research, and it
has been used to study curcumin and cisplatin (Baharuddin et al., 2015; Tung et al.,
2016). A cell migration assay was used to measure if the curcuminoids increased
cisplatin’s effect against A549 cellular migration into an area of a dish cleared of cells.
There were six different treatment groups: control, cisplatin, EF-24, CLEFMA, cisplatin
and EF-24, and cisplatin and CLEFMA. The percent wound recovery rate was measured
to see what the effect of cisplatin, and the curcuminoids alone or in combination with
cisplatin had on cancer cell migration.
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It was found that the cisplatin only, EF-24 only, and CLEFMA only treatment
groups did not significantly reduce the cell migration rate. However, the combination
groups (cisplatin and EF-24; cisplatin and CLEFMA) did significantly reduce the
migration rate. My results suggest that the two curcuminoids increased cisplatin’s
effectiveness against cancer cell migration.
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METHODS

Cell Migration Assay
This study used a cell migration assay to investigate how the curcuminoids alone
or with cisplatin treatment affected cancer cell migration. The A549 cell line was grown
in 10 cm diameter dishes in F12K media in an incubator (37 °C and 5% CO2). The cell
line was grown to approximately 90% confluence, and then the media was aspirated out.
Then, a scratch was made with a 200 μL pipet tip through the cell monolayer. Once the
wound was made, the cells were immediately treated with one of the following for 24
hours: 15 μM CLEFMA only, 2 μM EF-24 only, 10 μM cisplatin only, 10 μM cisplatin
with 15 μM CLEFMA, 10 μM cisplatin with 2 μM EF-24, and a media control. These
concentrations are the IC50 values determined in our lab during another project for the
A549 cell line. For the cisplatin with curcuminoid treatments, the curcuminoid was
added three hours after the cisplatin. This was to ensure that the cisplatin could enter the
cells and their nuclei (Park et al., 2012) before the curcuminoid vehicle, DMSO, which
can inactivate cisplatin (Hall et al., 2014), was introduced. For treatments where cisplatin
and a curcuminoid were combined, the wound was not made until after curcuminoid
addition. Each treatment category was performed in triplicate.
A Nikon camera (DS-5M) attached to a Nikon TMS microscope was used to take
pictures of the wound in the dishes at zero hours, the time the wound was made, and at
twenty-four hours after wound introduction (Figure 1). Then, the area of the wound was
measured using Adobe Photoshop’s lasso function. The percent wound recovery was
then calculated by subtracting the cleared area at 24 hours from the cleared area at 0
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hours and then dividing the resultant value by the original cleared area and converting to
a percentage.
Statistical Analysis
A one-way ANOVA with a Dunnett’s multiple comparison test was used to
analyze all migration assay results. The p value was set at 0.05.
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Figure 1: A549 cellular migration over a 24 hour treatment interval. A.-B. Photographs
taken from the same coordinate at a location of initial total A549 confluence in dishes
treated with F-12K media (vehicle control). A. t = 0 hours post-wound. B. t = 24 hours
post-wound.
6

RESULTS

This study used a cellular migration assay to assess whether cisplatin, EF-24,
CLEFMA or a combination of cisplatin with either curcuminoid altered A549 cellular
migration. Figure 2 shows wound examples corresponding to each treatment group. The
percent wound recovery for the cisplatin treatment group was 19.1%, which was not
statistically different (p > 0.05) than the control treatment group’s percent wound
recovery of 25% (Figure 3). The EF-24 and the CLEFMA only treatments had a percent
wound recovery of 21.9% and 22.8%, respectively. Both of these values, like cisplatin,
were also not statistically different (p > 0.05) from the control (Figure 4). However,
when cisplatin treatment was followed by either curcuminoid, the percent wound
recovery was significantly reduced (p < 0.05) compared to control (Figure 5). The
cisplatin and EF-24 treatment group had a percent wound recovery of 13.3%, and the
cisplatin and CLEFMA treatment group had a percent wound recovery of 12.8%. When
compared to cisplatin only, the combination treatments did not have a significant
difference in percent wound recovery (Figure 5). When the cisplatin only treatment
group is compared to the cisplatin and EF-24 group, there is a 5.8% difference, and when
compared to the cisplatin and CLEFMA treatment group, there is a 6.3% difference. The
difference between EF-24 only and the combination treatment of cisplatin and EF-24 is
8.6%; and the difference between CLEFMA only and the cisplatin and CLEFMA group
is 10%. Figure 6 shows a summary of all the treatment groups and their percent wound
recovery.
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Figure 2: Combining cisplatin with a curcuminoid caused A549 cell migration to
decrease. Color code (white box = control; red box = cisplatin only; green box = EF-24
only; blue box = CLEFMA only; red and green box = cisplatin with EF-24; red and blue
box = cisplatin with CLEFMA. A. Control (0 Hr). B. Control (24 Hr). C. Cisplatin (0 Hr).
D. Cisplatin (24 Hr). E. EF-24 (0 Hr). F. EF-24 (24 Hr). G. CLEFMA (0 Hr). H.
CLEFMA (24 Hr). I. Cisplatin + EF-24 (0 Hr). J. Cisplain + CLEFMA (0 Hr). L.
Cisplatin + CLEFMA (24 Hr).
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Figure 3: Cisplatin treatment does not reduce A549 migration compared to control. N =
3; p > 0.05.
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Figure 4: Combination of cisplatin and a curcuminoid decreased A549 wound recovery.
Curcuminoid treatment alone was not statistically different than vehicle control.
Combination of cisplatin with either EF-24 or CLEFMA significantly reduced migration.
N = 3; * p < 0.05.
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Figure 5: Curcuminoid and curcuminoid-cisplatin treatments do not alter A549 wound
recovery compared to cisplatin alone. N= 3; p > 0.05.
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Figure 6: Only the combination of cisplatin with a curcuminoid reduces A549 wound
recovery relative to the negative control. N = 3; * p < 0.05.
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DISCUSSION
Combining chemotherapy drugs that target different cell pathways could increase
their individual effects against cancer cell migration. Cisplatin treatment can decrease
migration in the A549 lung cancer cell line but can become ineffective due to the
development of resistance (Tung et al., 2016; Kim et al., 2017). Similarly, curcumin has
an effect against A549 lung cancer cell migration (Baharuddin et al., 2016; Jiao et al.,
2016). However, curcumin exhibits solubility issues, and therefore is inefficient to use in
cancer treatment (Skoupa et al., 2017). Because of this, we reasoned that the
curcuminoids EF-24 and CLEFMA, which are more soluble structural analogs of
curcumin (Skoupa et al., 2017; Sahoo et al., 2012), might have an effect against cancer
cell migration. Further, combinations of curcumin with cisplatin in the A549 cell line
caused migration to decrease (Baharuddin et al., 2016) which suggested to us that
treatment with both a curcuminoid and cisplatin might reduce cancer cell motility. We
used a cell migration assay to assess the effect of cisplatin, EF-24, CLEFMA, and
combinations of cisplatin with either curcuminoid against A549 lung cancer cell
migration.
We initially treated A549 cells with cisplatin or one of the curcuminoids to assess
if these compounds could individually reduce cell migration. Cisplatin did not
significantly reduce migration compared to vehicle control treatment (Figure 3; p > 0.05).
The percent wound recovery for the cisplatin treatment was 19.1%; whereas, vehicle
recovery was 25%. Similarly, both curcuminoids did not significantly reduce migration
(Figure 4; p > 0.05). The EF-24 only treatment group had a percent wound recovery of
21.9%, and the CLEFMA only treatment group had a percent wound recovery of 22.8%.
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These results indicate that cisplatin and curcuminoid treatment are ineffective against
cancer cell migration, but their combination does exhibit an increased effect against
migration (Figure 6; p < 0.05).
Both cisplatin and curcuminoid treatment together could decrease cancer cell
migration by targeting separate pathways that control motility. Cisplatin signals through
multiple pathways to effect cancer cell migration. For example in A549 cells, cisplatin
signals through a pathway incorporating transforming growth factor β1 (TGF-β1; Kim et
al., 2017). Sox2 and Wnt/β catenin signaling have also been implicated in A549 cell
migration during cisplatin treatment (He et al., 2017a). The microRNA, miR-146a,
modulates migration in cisplatin treated A549 cells through regulation on cyclin J, which
controls cell mitosis in oncogensis (Shi et al., 2017b). Like cisplatin, curcumin effects
cancer cell migration by signaling through discrete pathways. In A549 cells, treatment
with curcumin can reduce migration by modulating the microRNA, miR-330-5p, and
pathways incorporating mitogen-activated protein kinase, TGF-β and Wnt (Zhan et al.,
2017). Reduced migration due to modulation of c-Met, Akt, mTOR, and S6 in curcumin
treated A549 cells has also been reported (Jiao et al., 2016). As both cisplatin and
curcumin target some common cellular migration pathways, e.g., TGF-β and Wnt, in
A549, combining these two compounds could produce synergistic effects against
motility. Indeed, combinations of curcumin and cisplatin have reduced the invasive
property of A549 cells by downregulating Bcl-2 while upregulating Bax (He et al.,
2017b). Also, curcumin can improve cisplatin’s effect against A549 migration by
downregulating cyclin D1 and upregulating p21 mRNA expression (Baharuddin et al.,
2016). Further, the curcuminoid, H-4073, can enhance cisplatin’s effect against head and
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neck cancer migration by inhibiting the STAT, FAK, Akt, and VEGF pathways (Kumar
et al., 2014). The results obtained from combining cisplatin with curcumin or the
curcuminoid, H-4073, suggest that other curcuminoids such as EF-24 and CLEFMA
might also be able to enhance the effect of cisplatin against cancer cell migration.
Our investigation of the effects on migration from combining cisplatin with either
EF-24 or CLEFMA showed that together they significantly reduced A549 cell migration.
Cisplatin with EF-24 and CLEFMA significantly reduced cell migration to 13.3% and
12.8% of control treatment respectively (Figure 4; p < 0.05). Although, cisplatincurcuminoid treatment did not reduce migration significantly below that of cisplatin
alone (cisplatin-EF-24 = 5.8% and cisplatin-CLEFMA = 6.3%) (Figure 5; p > 0.05), a
greater, but still not significant reduction was seen between the individual curcuminoids
and their combination with cisplatin (EF-24 vs. cisplatin-EF-24 = 8.6% and CLEFMA vs.
cisplatin-CLEFMA = 10%) (Figure 4-5; p > 0.05). These results indicate that combining
cisplatin with either curcuminoid can enhance the effect of cisplatin alone against A549
cancer cell migration, although this effect does not appear to be either synergistic or
additive in nature.
Our results from combining EF-24 and CLEFMA suggest that they could signal
through different cellular motility pathways than cisplatin and enhance the platinum
compound’s effect against cancer cell migration. Although a comparative signal
transduction analysis of cisplatin and CLEFMA has not yet been performed, studies have
shown that EF-24 and cisplatin can signal through different pathways or target distinct
components of the same pathway. In cisplatin sensitive and resistant human ovarian
cancer cells, cisplatin does not induce caspase-3 expression; however, EF-24 induces the
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expression of this protein (Tan et al., 2010). In malignant mesothelioma cells, cisplatin
caused anti-apoptosis gene Bcl2 mRNA expression to decrease, but EF-24 did not have
this effect (Onen et al., 2015). Cisplatin and EF-24 might be able to effect migration by
acting on different components of the same pathway. EF-24 can form an adduct with the
antioxidant glutathione in leukemia cancer cells, which could be responsible for increased
ROS expression in these cells (Skoupa et al., 2017). However, cisplatin can reduce the
activity of another component of this antioxidant pathway, glutathione S-transferase, an
enzyme that binds glutathione to reactive oxygen species (Mukherjea and Rybak, 2011).
Thus, these studies suggest that cisplatin and one of our curcuminoids, EF-24, can target
distinct pathways or the same pathway by acting on different signaling components.
The cisplatin-curcuminoid treatments exhibited a significant decrease in migration
compared to control, but not when compared to either cisplatin or the curcuminoids alone
(Figure 6; p < 0.05). Even though cisplatin or the curcuminoids individually did not
reduce A549 migration, these treatments did cause a detectable reduction in migration
(Figure 6). If either cisplatin or a curcuminoid causes a non-significant effect against
migration in the same or separate pathways, then combining these compounds might
increase the effect in the same pathway or through summating signals traveling in
separate pathways, and then, the combination could induce a significant reduction in
cancer cell migration. Evidently, future work needs to be done to elaborate the precise
pathways that cisplatin, EF-24, and CLEFMA target in the A549 cell line. Having this
information will allow us to better understand how these compounds influence different
cancer cell migration signaling pathways and how these pathways intersect and regulate
each other.
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FUTURE DIRECTIONS
More research needs to be done on how these two curcuminoids increase
cisplatin’s effectiveness against cancer cell migration. Research conducted recently in
our laboratory has shown that combining either curcuminoid with cisplatin does not cause
a synergistic effect against A549 cancer cell viability. As increased reactive oxygen
species (ROS) release is implicated in cancer cell death, we have also investigated
whether cisplatin and the curcuminoids increased ROS release in A549 cells, and found
that the curcuminoids alone do not cause this effect and that combining cisplatin with a
curcuminoid reduced ROS levels (unpublished data). In the future, caspase and Western
blot assays will be used to identify which apoptotic pathways are modulated by cisplatin,
the curcuminoids and their combination in the A549 cell line. We hope that the
knowledge obtained from this research could prove to be valuable in the development of
future pharmaceutical interventions for treating lung and other cancers.
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